AU782994C - Treatment of refractory human tumors with epidermal growth factor receptor antagonists - Google Patents
Treatment of refractory human tumors with epidermal growth factor receptor antagonistsInfo
- Publication number
- AU782994C AU782994C AU46871/00A AU4687100A AU782994C AU 782994 C AU782994 C AU 782994C AU 46871/00 A AU46871/00 A AU 46871/00A AU 4687100 A AU4687100 A AU 4687100A AU 782994 C AU782994 C AU 782994C
- Authority
- AU
- Australia
- Prior art keywords
- antagonist
- egfr
- radiation
- tumors
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US31228499A | 1999-05-14 | 1999-05-14 | |
US09/312284 | 1999-05-14 | ||
US37402899A | 1999-08-13 | 1999-08-13 | |
US09/374028 | 1999-08-13 | ||
PCT/US2000/011756 WO2000069459A1 (en) | 1999-05-14 | 2000-05-01 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
Publications (3)
Publication Number | Publication Date |
---|---|
AU4687100A AU4687100A (en) | 2000-12-05 |
AU782994B2 AU782994B2 (en) | 2005-09-15 |
AU782994C true AU782994C (en) | 2006-08-24 |
Family
ID=26978320
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU46871/00A Ceased AU782994C (en) | 1999-05-14 | 2000-05-01 | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
Country Status (20)
Country | Link |
---|---|
US (3) | US20020012663A1 (ru) |
EP (2) | EP1218032A4 (ru) |
JP (2) | JP2003520195A (ru) |
KR (1) | KR20020000223A (ru) |
CN (1) | CN1200734C (ru) |
AU (1) | AU782994C (ru) |
BG (1) | BG106110A (ru) |
BR (1) | BR0010524A (ru) |
CA (1) | CA2373815A1 (ru) |
CZ (1) | CZ20014083A3 (ru) |
EE (1) | EE200100603A (ru) |
HK (1) | HK1047236A1 (ru) |
HU (1) | HUP0201480A3 (ru) |
IL (1) | IL146480A0 (ru) |
MX (1) | MXPA01011632A (ru) |
NO (1) | NO20015546L (ru) |
PL (1) | PL365999A1 (ru) |
RU (1) | RU2294761C2 (ru) |
SK (1) | SK16522001A3 (ru) |
WO (1) | WO2000069459A1 (ru) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US20030224001A1 (en) * | 1998-03-19 | 2003-12-04 | Goldstein Neil I. | Antibody and antibody fragments for inhibiting the growth of tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
EP1158985B1 (en) | 1999-01-13 | 2011-12-28 | Bayer HealthCare LLC | OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS |
US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
PL365999A1 (en) * | 1999-05-14 | 2005-01-24 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US7740841B1 (en) * | 2000-01-28 | 2010-06-22 | Sunnybrook Health Science Center | Therapeutic method for reducing angiogenesis |
WO2002011677A2 (en) * | 2000-08-09 | 2002-02-14 | Imclone Systems Incorporated | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists |
US20020151508A1 (en) * | 2001-02-09 | 2002-10-17 | Schering Corporation | Methods for treating proliferative diseases |
EP1236474A1 (en) * | 2001-02-26 | 2002-09-04 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Negative regulation of epidermal growth factor receptor activity by Mig-6 |
US20080008704A1 (en) * | 2001-03-16 | 2008-01-10 | Mark Rubin | Methods of treating colorectal cancer with anti-epidermal growth factor antibodies |
AU2002348477A1 (en) | 2001-05-01 | 2002-12-23 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
JP2004528368A (ja) * | 2001-05-08 | 2004-09-16 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 抗egfr抗体と抗ホルモン剤を用いた組合せ療法 |
DK2163256T3 (en) | 2001-05-11 | 2015-12-07 | Ludwig Inst For Cancer Res Ltd | Specific binding proteins and use thereof |
US20100056762A1 (en) | 2001-05-11 | 2010-03-04 | Old Lloyd J | Specific binding proteins and uses thereof |
KR100719624B1 (ko) * | 2001-05-18 | 2007-05-21 | 석정철 | 시각장애인을 위한 접착형 점자유도블록 및점자유도블록의 접착방법 |
DE60237282D1 (de) * | 2001-06-28 | 2010-09-23 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
US20050271663A1 (en) * | 2001-06-28 | 2005-12-08 | Domantis Limited | Compositions and methods for treating inflammatory disorders |
SI1478358T1 (sl) | 2002-02-11 | 2013-09-30 | Bayer Healthcare Llc | Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi |
ATE494000T1 (de) * | 2002-03-08 | 2011-01-15 | Max Planck Gesellschaft | Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs |
US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
EP1517921B1 (en) * | 2002-06-28 | 2006-06-07 | Domantis Limited | Dual specific ligands with increased serum half-life |
US7696320B2 (en) | 2004-08-24 | 2010-04-13 | Domantis Limited | Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor |
US20040147428A1 (en) * | 2002-11-15 | 2004-07-29 | Pluenneke John D. | Methods of treatment using an inhibitor of epidermal growth factor receptor |
TWI229650B (en) * | 2002-11-19 | 2005-03-21 | Sharp Kk | Substrate accommodating tray |
AU2003290330A1 (en) * | 2002-12-27 | 2004-07-22 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
US20060167026A1 (en) * | 2003-01-06 | 2006-07-27 | Hiroyuki Nawa | Antipsychotic molecular-targeting epithelial growth factor receptor |
EP1599484A2 (en) * | 2003-02-21 | 2005-11-30 | Chugai Seiyaku Kabushiki Kaisha | Process for the preparation of hexacyclic camptothecin derivatives |
UY28213A1 (es) | 2003-02-28 | 2004-09-30 | Bayer Pharmaceuticals Corp | Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos. |
DK1636585T3 (da) | 2003-05-20 | 2008-05-26 | Bayer Pharmaceuticals Corp | Diarylurinstoffer med kinasehæmmende aktivitet |
US20070036795A1 (en) | 2003-06-09 | 2007-02-15 | Samuel Waksal | Method of inhibiting receptor tyrosine kinases with an extracellular antagonist and an intracellular agonist |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
CL2004001834A1 (es) | 2003-07-23 | 2005-06-03 | Bayer Pharmaceuticals Corp | Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol |
WO2005027970A1 (ja) * | 2003-09-24 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | 癌治療用医薬 |
AU2004282219C1 (en) * | 2003-10-15 | 2009-12-17 | Osi Pharmaceuticals, Inc. | Imidazo [1, 5 - a] pyrazine tyrosine kinase inhibitors |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
JP4832426B2 (ja) | 2004-04-02 | 2011-12-07 | オーエスアイ・ファーマスーティカルズ・インコーポレーテッド | 6,6−二環置換されたヘテロ二環式タンパク質キナーゼ阻害剤 |
BRPI0509732A (pt) | 2004-04-09 | 2007-09-25 | Chugai Pharmaceutical Co Ltd | pró-fármaco solúvel em água, composição farmacêutica, agente terapêutico, agente antifungo e uso do referido pró-fármaco |
RU2006146612A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение цисплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
RU2006146623A (ru) * | 2004-06-03 | 2008-07-20 | Ф.Хоффманн-Ля Рош Аг (Ch) | Лечение оксалиплатином и ингибитором рецептора эпидермального фактора роста (egfr) |
AU2005249205A1 (en) * | 2004-06-03 | 2005-12-15 | F. Hoffmann-La Roche Ag | Treatment with gemcitabine and an EGFR-inhibitor |
NZ551355A (en) * | 2004-06-03 | 2009-09-25 | Hoffmann La Roche | Treatment of cancer with irinotecan (CPT-11) and erlotinib |
US20060084675A1 (en) * | 2004-10-18 | 2006-04-20 | Thomas Efferth | Combined treatment with artesunate and an epidermal growth factor receptor kinase inhibitor |
US20060084666A1 (en) * | 2004-10-18 | 2006-04-20 | Harari Paul M | Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor |
US20060084691A1 (en) * | 2004-10-18 | 2006-04-20 | Bilal Piperdi | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor |
US20070099856A1 (en) * | 2005-05-13 | 2007-05-03 | Gumerlock Paul H | Combined treatment with docetaxel and an epidermal growth factor receptor kinase inhibitor using an intermittent dosing regimen |
TW200744603A (en) * | 2005-08-22 | 2007-12-16 | Chugai Pharmaceutical Co Ltd | Novel anticancer concomitant drug |
KR20080066039A (ko) * | 2005-10-19 | 2008-07-15 | 추가이 세이야쿠 가부시키가이샤 | 신규 수용성 프로드러그를 함유하는 췌장암, 난소암 또는 간암의 예방 또는 치료제 |
WO2007049361A1 (ja) * | 2005-10-27 | 2007-05-03 | Stelic Corp. | 肝線維化抑制剤 |
JP2009519011A (ja) * | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | インターロイキン1受容体1型に結合する非競合ドメイン抗体フォーマット |
US8575164B2 (en) * | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007139930A2 (en) * | 2006-05-26 | 2007-12-06 | Bayer Healthcare Llc | Drug combinations with substituted diaryl ureas for the treatment of cancer |
KR100723641B1 (ko) * | 2006-06-07 | 2007-06-04 | 실버레이 주식회사 | 다중 조리가 가능한 솥 |
US20070286864A1 (en) * | 2006-06-09 | 2007-12-13 | Buck Elizabeth A | Combined treatment with an EGFR kinase inhibitor and an agent that sensitizes tumor cells to the effects of EGFR kinase inhibitors |
WO2008046107A2 (en) * | 2006-10-13 | 2008-04-17 | The Regents Of The University Of California | Novel inhibitors of the egfr kinase targeting the asymmetric activating dimer interface |
ES2609094T3 (es) * | 2007-01-25 | 2017-04-18 | Dana-Farber Cancer Institute, Inc. | Uso de anticuerpos anti-EGFR en el tratamiento de enfermedades mediadas por un EGFR mutante |
CN101688229B (zh) * | 2007-03-15 | 2013-06-12 | 路德维格癌症研究所 | 包含egfr抗体和src抑制剂的组合物及其在制备用于治疗哺乳动物癌症的药物中的用途 |
CA2683801A1 (en) * | 2007-06-06 | 2008-12-11 | Domantis Limited | Polypeptides, antibody variable domains and antagonists |
US9283276B2 (en) | 2007-08-14 | 2016-03-15 | Ludwig Institute For Cancer Research Ltd. | Monoclonal antibody 175 targeting the EGF receptor and derivatives and uses thereof |
US20100323957A1 (en) * | 2007-11-19 | 2010-12-23 | The Regents Of The University Of California The Office Of The President | Novel assay for inhibitors of egfr |
JP2011510018A (ja) * | 2008-01-18 | 2011-03-31 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 癌治療のためのイミダゾピラジノール誘導体 |
KR20100131446A (ko) * | 2008-03-05 | 2010-12-15 | 노파르티스 아게 | Egfr 의존성 질환 또는 egfr 족 구성원을 표적으로 하는 작용제에 대한 내성을 획득한 질환의 치료를 위한 피리미딘 유도체의 용도 |
ES2396613T3 (es) * | 2008-05-19 | 2013-02-22 | OSI Pharmaceuticals, LLC | Imidazopirazinas e imidazotriazinas sustituidas |
EP2408479A1 (en) | 2009-03-18 | 2012-01-25 | OSI Pharmaceuticals, LLC | Combination cancer therapy comprising administration of an egfr inhibitor and an igf-1r inhibitor |
MA33198B1 (fr) * | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
CN102405214A (zh) | 2009-04-20 | 2012-04-04 | Osi药物有限责任公司 | C-吡嗪-甲胺的制备 |
JP2012526138A (ja) * | 2009-05-07 | 2012-10-25 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 副腎皮質癌を治療するためのosi−906の使用 |
US20110076232A1 (en) * | 2009-09-29 | 2011-03-31 | Ludwig Institute For Cancer Research | Specific binding proteins and uses thereof |
BR112012029057A2 (pt) | 2010-05-14 | 2020-10-13 | Dana-Farber Cancer Institute, Inc. | composições e métodos de tratamento de leucemia |
SI2902030T1 (sl) | 2010-05-14 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Tienotriazolodiazepinske spojine za zdravljenje neoplazije |
RU2457546C1 (ru) * | 2011-03-09 | 2012-07-27 | Учреждение Российской академии медицинских наук Научный центр реконструктивной и восстановительной хирургии Сибирского отделения РАМН (НЦРВХ СО РАМН) | Способ моделирования аденокарциномы толстой кишки человека |
WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
JP6088488B2 (ja) | 2011-04-21 | 2017-03-01 | シアトル ジェネティックス, インコーポレイテッド | 新規な結合剤−薬物複合体(adc)およびそれらの使用 |
MX2014002436A (es) | 2011-08-31 | 2014-05-27 | Genentech Inc | Marcadores de diagnostico. |
JP2014531213A (ja) | 2011-09-30 | 2014-11-27 | ジェネンテック, インコーポレイテッド | 上皮又は間葉の表現型の診断用メチル化マーカー、及び腫瘍又は腫瘍細胞におけるegfrキナーゼ阻害薬に対する応答 |
MX2016005980A (es) | 2013-11-08 | 2016-12-09 | Dana Farber Cancer Inst Inc | Terapia de combinación para el cáncer usando inhibidores de la proteína bromodominio y extra-terminal. |
JP2017506666A (ja) | 2014-02-28 | 2017-03-09 | テンシャ セラピューティクス,インコーポレイテッド | 高インスリン血症に関連した症状の処置 |
CN107002119A (zh) | 2014-03-24 | 2017-08-01 | 豪夫迈·罗氏有限公司 | 使用c‑met拮抗剂的癌症治疗及前者与hgf表达的关联 |
US11649291B2 (en) | 2016-05-24 | 2023-05-16 | Insmed Incorporated | Antibodies and methods of making same |
WO2019017401A1 (ja) * | 2017-07-18 | 2019-01-24 | 協和発酵キリン株式会社 | 抗ヒトccr1モノクローナル抗体 |
AU2019247434A1 (en) * | 2018-04-06 | 2020-10-08 | Seagen Inc. | Camptothecin Peptide Conjugates |
Family Cites Families (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CU22545A1 (es) * | 1994-11-18 | 1999-03-31 | Centro Inmunologia Molecular | Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico |
NL7802170A (nl) * | 1977-04-18 | 1978-10-20 | Hitachi Metals Ltd | Sierraad. |
US4510924A (en) * | 1980-07-10 | 1985-04-16 | Yale-New Haven Hospital, Inc. | Brachytherapy devices and methods employing americium-241 |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4943533A (en) | 1984-03-01 | 1990-07-24 | The Regents Of The University Of California | Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor |
US5866363A (en) * | 1985-08-28 | 1999-02-02 | Pieczenik; George | Method and means for sorting and identifying biological information |
US4816401A (en) * | 1985-09-09 | 1989-03-28 | University Of Rochester | Serum free cell culture medium |
CA1275922C (en) * | 1985-11-28 | 1990-11-06 | Harunobu Amagase | Treatment of cancer |
US4846782A (en) | 1986-03-14 | 1989-07-11 | Schering Corporation | Treatment of cancer with interferon and radiotherapy |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4763642A (en) * | 1986-04-07 | 1988-08-16 | Horowitz Bruce S | Intracavitational brachytherapy |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US5260203A (en) * | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
JP3040121B2 (ja) * | 1988-01-12 | 2000-05-08 | ジェネンテク,インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
US5470571A (en) * | 1988-01-27 | 1995-11-28 | The Wistar Institute | Method of treating human EGF receptor-expressing gliomas using radiolabeled EGF receptor-specific MAB 425 |
IL89489A0 (en) | 1988-03-09 | 1989-09-10 | Hybritech Inc | Chimeric antibodies directed against human carcinoembryonic antigen |
WO1989009622A1 (en) | 1988-04-15 | 1989-10-19 | Protein Design Labs, Inc. | Il-2 receptor-specific chimeric antibodies |
WO1989009825A1 (en) | 1988-04-16 | 1989-10-19 | Celltech Limited | Method for producing recombinant dna proteins |
AU4128089A (en) * | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
ES2133271T3 (es) * | 1989-07-06 | 1999-09-16 | Univ California | Receptores para factores de crecimiento de fibroblastos. |
US5705157A (en) * | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
US5196446A (en) | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
AU662311B2 (en) | 1991-02-05 | 1995-08-31 | Novartis Ag | Recombinant antibodies specific for a growth factor receptor |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
US5480883A (en) | 1991-05-10 | 1996-01-02 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase |
DK0590058T3 (da) * | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
WO1993011236A1 (en) * | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
AU661533B2 (en) | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
AU4025193A (en) | 1992-04-08 | 1993-11-18 | Cetus Oncology Corporation | Humanized C-erbB-2 specific antibodies |
US6177401B1 (en) * | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
DK0672142T3 (da) * | 1992-12-04 | 2001-06-18 | Medical Res Council | Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse |
US5855885A (en) * | 1993-01-22 | 1999-01-05 | Smith; Rodger | Isolation and production of catalytic antibodies using phage technology |
US5550114A (en) * | 1993-04-02 | 1996-08-27 | Thomas Jefferson University | Epidermal growth factor inhibitor |
US5654307A (en) | 1994-01-25 | 1997-08-05 | Warner-Lambert Company | Bicyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
US5861499A (en) * | 1994-02-10 | 1999-01-19 | Imclone Systems Incorporated | Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain |
US6448077B1 (en) * | 1994-02-10 | 2002-09-10 | Imclone Systems, Inc. | Chimeric and humanized monoclonal antibodies specific to VEGF receptors |
US5840301A (en) * | 1994-02-10 | 1998-11-24 | Imclone Systems Incorporated | Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors |
EP0746554A1 (en) * | 1994-02-23 | 1996-12-11 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
AU2096895A (en) * | 1994-03-07 | 1995-09-25 | Sugen, Incorporated | Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof |
RU2170257C2 (ru) * | 1994-03-17 | 2001-07-10 | Мерк Патент Гмбх | Анти-эфрр одноцепочечный fv, химерное анти-эфрр антитело и способ его получения, фармацевтическая композиция для лечения опухолей, средство для диагностики локализации или оценки роста опухоли |
US5656655A (en) | 1994-03-17 | 1997-08-12 | Rhone-Poulenc Rorer Pharmaceuticals, Inc. | Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase |
US5869465A (en) * | 1994-04-08 | 1999-02-09 | Receptagen Corporation | Methods of receptor modulation and uses therefor |
US5468754A (en) | 1994-04-19 | 1995-11-21 | Bionumerik Pharmaceuticals, Inc. | 11,7 substituted camptothecin derivatives and formulations of 11,7 substituted camptothecin derivatives and methods for uses thereof |
US5604233A (en) | 1994-04-28 | 1997-02-18 | Bionumerik Pharmaceuticals, Inc. | Lactone stable formulation of 7-ethyl camptothecin and methods for uses thereof |
US5626862A (en) * | 1994-08-02 | 1997-05-06 | Massachusetts Institute Of Technology | Controlled local delivery of chemotherapeutic agents for treating solid tumors |
GB9508538D0 (en) * | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
US5663144A (en) * | 1995-05-03 | 1997-09-02 | The Trustees Of The University Of Pennsylvania | Compounds that bind to p185 and methods of using the same |
US5726181A (en) | 1995-06-05 | 1998-03-10 | Bionumerik Pharmaceuticals, Inc. | Formulations and compositions of poorly water soluble camptothecin derivatives |
AU6267896A (en) * | 1995-06-07 | 1996-12-30 | Imclone Systems Incorporated | Antibody and antibody fragments for inhibiting the growth oftumors |
US7060808B1 (en) * | 1995-06-07 | 2006-06-13 | Imclone Systems Incorporated | Humanized anti-EGF receptor monoclonal antibody |
US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
EP0888349B1 (en) * | 1996-01-23 | 2002-05-22 | Novartis AG | Pyrrolopyrimidines and processes for their preparation |
GB9603095D0 (en) * | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
GB9707800D0 (en) * | 1996-05-06 | 1997-06-04 | Zeneca Ltd | Chemical compounds |
US5925566A (en) * | 1996-06-06 | 1999-07-20 | University Of Massachusetts | Non-activated receptor complex proteins and uses thereof |
US6004967A (en) * | 1996-09-13 | 1999-12-21 | Sugen, Inc. | Psoriasis treatment with quinazoline compounds |
US5942602A (en) * | 1997-02-13 | 1999-08-24 | Schering Aktiengessellschaft | Growth factor receptor antibodies |
US20030105057A1 (en) * | 1997-03-19 | 2003-06-05 | Yale University | Methods and compositions for stimulating apoptosis and cell death or for inhibiting cell growth and cell attachment |
US5914269A (en) * | 1997-04-04 | 1999-06-22 | Isis Pharmaceuticals, Inc. | Oligonucleotide inhibition of epidermal growth factor receptor expression |
US6235883B1 (en) * | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
US20020173629A1 (en) * | 1997-05-05 | 2002-11-21 | Aya Jakobovits | Human monoclonal antibodies to epidermal growth factor receptor |
US6417168B1 (en) * | 1998-03-04 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods of treating tumors |
ZA200007412B (en) * | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
US7396810B1 (en) * | 2000-08-14 | 2008-07-08 | Oregon Health Sciences University | Compositions and methods for treating cancer by modulating HER-2 and EGF receptors |
PL365999A1 (en) * | 1999-05-14 | 2005-01-24 | Imclone Systems Incorporated | Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
US6627196B1 (en) * | 1999-08-27 | 2003-09-30 | Genentech, Inc. | Dosages for treatment with anti-ErbB2 antibodies |
JP2004529610A (ja) * | 2000-10-13 | 2004-09-30 | ユーエイビー リサーチ ファンデーション | ヒト抗上皮増殖因子受容体一本鎖抗体 |
AU2002239486A1 (en) * | 2000-12-08 | 2002-06-18 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
WO2002087618A1 (fr) * | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
CZ200438A3 (cs) * | 2001-06-13 | 2004-06-16 | Genmab A/S | Název neuveden |
US7595378B2 (en) * | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
DE10163459A1 (de) * | 2001-12-21 | 2003-07-03 | Merck Patent Gmbh | Lyophilisierte Zubereitung enthaltend Antikörper gegen EGF-Rezeptor |
ATE494000T1 (de) * | 2002-03-08 | 2011-01-15 | Max Planck Gesellschaft | Verwendung von egfr transaktivierungsinhibitoren für menschlichen krebs |
US20060264353A1 (en) * | 2002-03-21 | 2006-11-23 | Maxey Kirk M | Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension |
AU2003241898A1 (en) * | 2002-06-03 | 2003-12-19 | Mitsubishi Pharma Corporation | PREVENTIVES AND/OR REMEDIES FOR SUBJECTS WITH THE EXPRESSION OR ACTIVATION OF Her2 AND/OR EGFR |
MXPA05003796A (es) * | 2002-10-10 | 2006-02-22 | Merck Patent Gmbh | Anticuerpos anti-erb-b biespecificos y su uso en terapia de tumor. |
EP1493445A1 (en) * | 2003-07-04 | 2005-01-05 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibition of stress-induced ligand-dependent EGFR activation |
ES2352697T3 (es) * | 2003-11-07 | 2011-02-22 | Ablynx N.V. | Anticuerpos de dominio único de camelidae vhh dirigidos contra el receptor del factor de crecimiento epidérmico y usos de los mismos. |
DE10355904A1 (de) * | 2003-11-29 | 2005-06-30 | Merck Patent Gmbh | Feste Formen von anti-EGFR-Antikörpern |
CN1953768B (zh) * | 2004-02-12 | 2010-10-13 | 默克专利有限公司 | 抗-egfr抗体的高浓缩液体制剂 |
TW200533339A (en) * | 2004-03-16 | 2005-10-16 | Bristol Myers Squibb Co | Therapeutic synergy of anti-cancer compounds |
ES2387809T3 (es) * | 2004-03-19 | 2012-10-02 | Imclone Llc | Anticuerpo frente al receptor del factor de crecimiento epidérmico humano |
PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
-
2000
- 2000-05-01 PL PL00365999A patent/PL365999A1/xx not_active IP Right Cessation
- 2000-05-01 SK SK1652-2001A patent/SK16522001A3/sk unknown
- 2000-05-01 AU AU46871/00A patent/AU782994C/en not_active Ceased
- 2000-05-01 EE EEP200100603A patent/EE200100603A/xx unknown
- 2000-05-01 EP EP00928671A patent/EP1218032A4/en not_active Withdrawn
- 2000-05-01 CZ CZ20014083A patent/CZ20014083A3/cs unknown
- 2000-05-01 IL IL14648000A patent/IL146480A0/xx unknown
- 2000-05-01 BR BR0010524-4A patent/BR0010524A/pt not_active IP Right Cessation
- 2000-05-01 MX MXPA01011632A patent/MXPA01011632A/es not_active Application Discontinuation
- 2000-05-01 WO PCT/US2000/011756 patent/WO2000069459A1/en active IP Right Grant
- 2000-05-01 CN CNB008103216A patent/CN1200734C/zh not_active Expired - Fee Related
- 2000-05-01 JP JP2000617919A patent/JP2003520195A/ja active Pending
- 2000-05-01 EP EP08015392A patent/EP2042194A3/en not_active Withdrawn
- 2000-05-01 RU RU2001130771/14A patent/RU2294761C2/ru active
- 2000-05-01 HU HU0201480A patent/HUP0201480A3/hu unknown
- 2000-05-01 KR KR1020017014494A patent/KR20020000223A/ko not_active Application Discontinuation
- 2000-05-01 CA CA002373815A patent/CA2373815A1/en not_active Abandoned
-
2001
- 2001-04-24 US US09/840,146 patent/US20020012663A1/en not_active Abandoned
- 2001-11-13 NO NO20015546A patent/NO20015546L/no not_active Application Discontinuation
- 2001-11-14 BG BG106110A patent/BG106110A/bg unknown
- 2001-11-30 US US09/996,954 patent/US20030157104A1/en not_active Abandoned
-
2002
- 2002-12-03 HK HK02108768.1A patent/HK1047236A1/zh unknown
-
2004
- 2004-12-20 US US11/018,950 patent/US20050112120A1/en not_active Abandoned
-
2008
- 2008-09-24 JP JP2008244928A patent/JP2009120583A/ja active Pending
Non-Patent Citations (3)
Title |
---|
BASALGA ET AL. BACAST CAN RES. & TAGAT,1994,VOL.29,P127-138 * |
BRADY LW ET AL; J NEUROSURG SCI, JUL-DEC 1990, 34(3-4)P243-9 * |
HAN ET AL. ONC RES. 1997, VOL.9, P 581-587 * |
Also Published As
Publication number | Publication date |
---|---|
CN1200734C (zh) | 2005-05-11 |
NO20015546L (no) | 2002-01-14 |
US20020012663A1 (en) | 2002-01-31 |
CA2373815A1 (en) | 2000-11-23 |
BR0010524A (pt) | 2002-05-28 |
IL146480A0 (en) | 2002-07-25 |
WO2000069459A1 (en) | 2000-11-23 |
AU782994B2 (en) | 2005-09-15 |
NO20015546D0 (no) | 2001-11-13 |
EP1218032A1 (en) | 2002-07-03 |
BG106110A (bg) | 2002-04-30 |
EP1218032A4 (en) | 2005-05-25 |
EE200100603A (et) | 2003-02-17 |
HUP0201480A2 (en) | 2002-08-28 |
CZ20014083A3 (cs) | 2002-08-14 |
EP2042194A2 (en) | 2009-04-01 |
PL365999A1 (en) | 2005-01-24 |
HUP0201480A3 (en) | 2009-03-30 |
HK1047236A1 (zh) | 2003-02-14 |
CN1361700A (zh) | 2002-07-31 |
US20050112120A1 (en) | 2005-05-26 |
KR20020000223A (ko) | 2002-01-05 |
JP2009120583A (ja) | 2009-06-04 |
EP2042194A3 (en) | 2009-04-22 |
SK16522001A3 (sk) | 2002-10-08 |
JP2003520195A (ja) | 2003-07-02 |
US20030157104A1 (en) | 2003-08-21 |
MXPA01011632A (es) | 2002-11-07 |
AU4687100A (en) | 2000-12-05 |
RU2294761C2 (ru) | 2007-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU782994C (en) | Treatment of refractory human tumors with epidermal growth factor receptor antagonists | |
US20090297509A1 (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases | |
RU2531758C2 (ru) | Моноклональные антитела для лечения опухолей | |
US9522956B2 (en) | Combination therapy using anti-EGFR and anti-HER2 antibodies | |
AU2001295002B2 (en) | Treatment of hyperproliferative diseases with epidermal growth factor receptor antagonists | |
SK17282000A3 (sk) | Nerádioaktívne označený inhibítor proteínového tyrozínkynázového receptora | |
US20030202973A1 (en) | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists | |
AU2004200705A1 (en) | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |